Omalizumab in Chronic Spontaneous Urticaria Refractory to Conventional Therapy: An Italian Retrospective Clinical Analysis with Suggestions for Long-Term Maintenance Strategies

INTRODUCTION: Omalizumab is indicated for the treatment of patients affected by chronic spontaneous urticaria (CSU) refractory to antihistamines. The aim of this study was to assess the efficacy, safety, and recurrence of symptoms in a real-life experience of omalizumab as an add-on therapy for H(1)...

Descripción completa

Detalles Bibliográficos
Autores principales: Mandel, Victor D., Guanti, Mario B., Liberati, Serena, Demonte, Antongiulio, Pellacani, Giovanni, Pepe, Patrizia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6002323/
https://www.ncbi.nlm.nih.gov/pubmed/29770909
http://dx.doi.org/10.1007/s13555-018-0240-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6002323/
https://www.ncbi.nlm.nih.gov/pubmed/29770909
http://dx.doi.org/10.1007/s13555-018-0240-7

Ejemplares similares